I. Dogan Et Al. , "Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3, 2021
Dogan, I. Et Al. 2021. Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3 .
Dogan, I., Tastekin, D., Karabulut, S., & Sakar, B., (2021). Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3.
Dogan, İzzet Et Al. "Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3, 2021
Dogan, İzzet Et Al. "Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3, 2021
Dogan, I. Et Al. (2021) . "Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3.
@article{article, author={İzzet DOĞAN Et Al. }, title={Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}